Pharmacokinetic and pharmacodynamic modelling for renal function dependent urinary glucose excretion effect of ipragliflozin, a selective sodium–glucose cotransporter 2 inhibitor, both in healthy subjects and patients with type 2 diabetes mellitus

AIMS: To provide a model‐based prediction of individual urinary glucose excretion (UGE) effect of ipragliflozin, we constructed a pharmacokinetic/pharmacodynamic (PK/PD) model and a population PK model using pooled data of clinical studies. METHODS: A PK/PD model for the change from baseline in UGE...

Descripción completa

Detalles Bibliográficos
Autores principales: Saito, Masako, Kaibara, Atsunori, Kadokura, Takeshi, Toyoshima, Junko, Yoshida, Satoshi, Kazuta, Kenichi, Ueyama, Eiji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6624389/
https://www.ncbi.nlm.nih.gov/pubmed/31026084
http://dx.doi.org/10.1111/bcp.13972

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6624389/
https://www.ncbi.nlm.nih.gov/pubmed/31026084
http://dx.doi.org/10.1111/bcp.13972

Ejemplares similares